

# **Certificate of Analysis**

Print Date: Mar 12th 2020

www.tocris.com

Product Name: TMI 1 Catalog No.: 5960 Batch No.: 1

CAS Number: 287403-39-8

IUPAC Name: (3S)-4-[[4-(2-Butyn-1-yloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-3-thiomorpholinecarboxamide

### 1. PHYSICAL AND CHEMICAL PROPERTIES

**Batch Molecular Formula:**  $C_{17}H_{22}N_2O_5S_2$ 

Batch Molecular Weight: 398.49
Physical Appearance: White solid

Solubility: DMSO to 100 mM

ethanol to 20 mM

Storage: Store at -20°C

**Batch Molecular Structure:** 

### 2. ANALYTICAL DATA

**HPLC:** Shows 99.4% purity

<sup>1</sup>H NMR: Consistent with structure

Mass Spectrum: Consistent with structure

Microanalysis: Carbon Hydrogen Nitrogen

Theoretical 51.24 5.56 7.03 Found 51.15 5.6 6.95

www.tocris.com/distributors Tel:+1 612 379 2956



## **Product Information**

Print Date: Mar 12th 2020

www.tocris.com

Product Name: TMI 1 Catalog No.: 5960 Batch No.: 1

CAS Number: 287403-39-8

IUPAC Name: (3S)-4-[[4-(2-Butyn-1-yloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-3-thiomorpholinecarboxamide

### **Description:**

ADAM17 (TACE) and MMP inhibitor (IC $_{50}$  values are 3, 4.7, 6.6, 8.4, 12, 26 and 26 nM for MMP-13, MMP-2, MMP-1, ADAM 17, MMP-9, MMP-7 and MMP-14, respectively). Suppresses TNF- $\alpha$  production in an acute LPS-mouse model. Reduces severity score in an in vivo model of rheumatoid arthritis. Displays selective cytotoxicity to tumor cells and cancer stem cells in vitro. Induces tumor apoptosis in a breast cancer in vivo model. Orally bioavailable.

### **Physical and Chemical Properties:**

Batch Molecular Formula: C<sub>17</sub>H<sub>22</sub>N<sub>2</sub>O<sub>5</sub>S<sub>2</sub>

Batch Molecular Weight: 398.49 Physical Appearance: White solid

### Minimum Purity: ≥98%

### **Batch Molecular Structure:**

Storage: Store at -20°C

### Solubility & Usage Info:

DMSO to 100 mM ethanol to 20 mM

### Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

### **Licensing Information:**

Sold for research purposes under agreement from Pfizer Inc

#### References:

Mezil et al (2012) Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer PLoS One 7 e43409. PMID: 23028451.

Levin (2006) Heterocyclic inhibitors of tumor necrosis factor-α converting enzyme (TACE) Heterocycles 70 691.

**Zhang** et al (2004) Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]]sulfonyl]-N-hydroxy-2,2-dimethyl-(3*S*) thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor- $\alpha$ -converting enzyme/matrix meta J.Pharmacol.Exp.Ther. **309** 348. PMID: 14718605.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use